Developer docs
API playgroundTry for free, no card

Search company profiles

Bionic Vision Technologies

Full company profile

uuid0003k2f

Namestring
Bionic Vision Technologies
Websiteurl
bionicvis.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Bionic Vision Technologies is a privately held Australian medical device company founded in 2010 and headquartered in Melbourne, Australia. The company develops visual prostheses designed to restore functional vision to individuals who are blind, operating within the neuroprosthetics and bionic contact lenses market segments. Its core work targets retinal diseases and visual impairment through prosthetic device development, addressing an addressable market projected to reach $0.53 billion by 2030 across augmented reality, health monitoring, and vision correction applications.

The company operates with a lean team of 1-10 employees led by CEO Ash Attia, Executive Chairman Robert Klupacs, COO Adrian Oates, CTO Brian Gordon, and directors Er Gad Gold and Andrew Rudge. Its technology appears to be at the research and development stage, as no commercial products, pricing models, regulatory clearances, or manufacturing capabilities are disclosed in available sources. The company has been recognized through the MedTech Innovator accelerator program (2014) and received $18 million in Series 2 funding in April 2017 from China Huarong International Holdings and State Path Capital Limited.

The company's business model is not publicly disclosed, with no revenue figures, pricing structures, customer segments, or go-to-market details available in the input data. Operating status is confirmed as active based on inclusion in current neuroprosthetics market reports, but no products, patents, partnerships, certifications, or geographic markets served are explicitly documented. The lack of disclosed post-2017 activity limits visibility into current commercialization progress, and the company should be assessed as a pre-commercial, R&D-stage medical device venture in a capital-intensive regulatory pathway.

Short descriptiontext

Bionic Vision Technologies is a privately held Australian medical device company founded in 2010 that develops visual prostheses to restore vision in blind individuals, operating from Melbourne in the neuroprosthetics and bionic contact lenses market segments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDocklands, Australia
HQ citystring
Docklands
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
visual prosthesis systems, retinal implants, bionic eye devices, neuroprosthetic technology, vision restoration devices
Industry2 codes
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Visual Prosthetics / Bionic Eye Systems
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bionic Vision Technologies develops visual prostheses designed to restore functional vision to people blinded by retinal degenerative diseases. The company's core offering is a bionic eye system that uses electrical stimulation of the retina to produce a sense of vision in patients who have lost sight. The company is based in Melbourne, Australia, and is in the development and clinical-trial stage of bringing this medical device to market.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Bionic Eye Visual Prosthesis System
CategoryVisual Prosthetics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers5 records
1Cortigent (formerly Second Sight Medical Products)
TypeDirect peer
Description

Cortigent is the most direct competitor in visual prosthetics, having developed and commercialized the Argus II retinal prosthesis system. It serves the same target population of patients with retinitis pigmentosa and outer retinal degeneration.

TypeEmerging player
Description

Nano Retina is an Israeli company developing the NR600 implantable artificial retina, addressing the same blindness-from-retinal-degeneration market with a miniaturized implant approach.

TypeDirect peer
Description

Pixium Vision is a French company developing the Prima retinal prosthesis system for age-related macular degeneration. It is a direct peer in the visual prosthesis space targeting the same patient populations with a similar technological approach.

4Retina Implant AG
TypeDirect peer
Description

Retina Implant AG developed subretinal implants for retinitis pigmentosa patients, representing a direct competitor with similar retinal stimulation technology and target indications.

TypeEmerging player
Description

iBionics is an emerging player developing diamond-based retinal implants to restore vision. It addresses the same blindness market with a differentiated electrode technology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionic Vision Technologies

Visual Prosthetics / Bionic Eye Systemsbionicvis.com

Bionic Vision Technologies is a privately held Australian medical device company founded in 2010 that develops visual prostheses to restore vision in blind individuals, operating from Melbourne in the neuroprosthetics and bionic contact lenses market segments.

What Bionic Vision Technologies does

Bionic Vision Technologies is a privately held Australian medical device company founded in 2010 and headquartered in Melbourne, Australia. The company develops visual prostheses designed to restore functional vision to individuals who are blind, operating within the neuroprosthetics and bionic contact lenses market segments. Its core work targets retinal diseases and visual impairment through prosthetic device development, addressing an addressable market projected to reach $0.53 billion by 2030 across augmented reality, health monitoring, and vision correction applications.

The company operates with a lean team of 1-10 employees led by CEO Ash Attia, Executive Chairman Robert Klupacs, COO Adrian Oates, CTO Brian Gordon, and directors Er Gad Gold and Andrew Rudge. Its technology appears to be at the research and development stage, as no commercial products, pricing models, regulatory clearances, or manufacturing capabilities are disclosed in available sources. The company has been recognized through the MedTech Innovator accelerator program (2014) and received $18 million in Series 2 funding in April 2017 from China Huarong International Holdings and State Path Capital Limited.

The company's business model is not publicly disclosed, with no revenue figures, pricing structures, customer segments, or go-to-market details available in the input data. Operating status is confirmed as active based on inclusion in current neuroprosthetics market reports, but no products, patents, partnerships, certifications, or geographic markets served are explicitly documented. The lack of disclosed post-2017 activity limits visibility into current commercialization progress, and the company should be assessed as a pre-commercial, R&D-stage medical device venture in a capital-intensive regulatory pathway.

Bionic Vision Technologies firmographics

Firmographics
Name
Bionic Vision Technologies
Website
https://bionicvis.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Bionic Vision Technologies is a privately held Australian medical device company founded in 2010 that develops visual prostheses to restore vision in blind individuals, operating from Melbourne in the neuroprosthetics and bionic contact lenses market segments.
Ownership category
akta.pro rank

Bionic Vision Technologies industry classification

Industry
Product category
Visual Prosthetics / Bionic Eye Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Visual prosthesis systems
  • Retinal implants
  • Bionic eye devices
  • Neuroprosthetic technology
  • Vision restoration devices

Where Bionic Vision Technologies is headquartered

Location

Headquarters

HQ city
Docklands
HQ country
Australia
HQ region
Oceania

Markets served

Bionic Vision Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Bionic Vision Technologies product offering

Product offering

Core offering

Bionic Vision Technologies develops visual prostheses designed to restore functional vision to people blinded by retinal degenerative diseases. The company's core offering is a bionic eye system that uses electrical stimulation of the retina to produce a sense of vision in patients who have lost sight. The company is based in Melbourne, Australia, and is in the development and clinical-trial stage of bringing this medical device to market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bionic Eye Visual Prosthesis System

Companies that use Bionic Vision Technologies

Customer profile

Ideal customer profiles1 record

Bionic Vision Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Bionic Vision Technologies partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights3 records

Bionic Vision Technologies competitors and assessment

Company assessment

Direct peers

  • Cortigent (formerly Second Sight Medical Products): Cortigent is the most direct competitor in visual prosthetics, having developed and commercialized the Argus II retinal prosthesis system. It serves the same target population of patients with retinitis pigmentosa and outer retinal degeneration.
  • Pixium Vision: Pixium Vision is a French company developing the Prima retinal prosthesis system for age-related macular degeneration. It is a direct peer in the visual prosthesis space targeting the same patient populations with a similar technological approach.
  • Retina Implant AG: Retina Implant AG developed subretinal implants for retinitis pigmentosa patients, representing a direct competitor with similar retinal stimulation technology and target indications.

Emerging players

  • Nano Retina: Nano Retina is an Israeli company developing the NR600 implantable artificial retina, addressing the same blindness-from-retinal-degeneration market with a miniaturized implant approach.
  • iBionics (Canadian company): iBionics is an emerging player developing diamond-based retinal implants to restore vision. It addresses the same blindness market with a differentiated electrode technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Bionic Vision Technologies social profiles

Digital presence

Bionic Vision Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionic Vision Technologies leadership team

Management profile

Number of profiles

Profiles6 records

Bionic Vision Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionic Vision Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionic Vision Technologies

What does Bionic Vision Technologies do?

Bionic Vision Technologies develops visual prostheses designed to restore functional vision to people blinded by retinal degenerative diseases. The company's core offering is a bionic eye system that uses electrical stimulation of the retina to produce a sense of vision in patients who have lost sight. The company is based in Melbourne, Australia, and is in the development and clinical-trial stage of bringing this medical device to market.

When was Bionic Vision Technologies founded?

Bionic Vision Technologies was founded in 2010. It employs 1 to 10 people.

Where is Bionic Vision Technologies based?

Bionic Vision Technologies is headquartered in Docklands, Australia, in the Oceania region.

Who are Bionic Vision Technologies's main competitors?

Direct peers on record are Cortigent (formerly Second Sight Medical Products), Pixium Vision and Retina Implant AG. Emerging players are Nano Retina and iBionics (Canadian company).

Does Bionic Vision Technologies have an API?

No public API is recorded for Bionic Vision Technologies.

What industry is Bionic Vision Technologies in?

Bionic Vision Technologies's product category is Visual Prosthetics / Bionic Eye Systems. Its primary akta.pro industry code is HLAHAJAN, Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids), with a secondary code of HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The AustralianNewspaper home delivery, website, iPad, iPhone & Android appsState Path Capital, a Hong Kong-based investment firm connected to Li Ka-shing, is preparing to announce a major acquisition of an Australian biotech company to expand its medical device operations in China. The firm is also finalizing an Australian market listing for Bionic Vision Technologies, in which it previously invested.PR NewswireBionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund GrantBionic Vision Technologies (BVT) has begun the next phase of development for its Australian bionic eye technology after receiving a AU$1 million grant from the Australian Government's Medical Research Future Fund's BioMedTech Horizons 3.0 program in late 2020. The funding will be used to finalise sophisticated vision processing software that converts images from smart glasses into brain-stimulating signals for users with retinitis pigmentosa. The next-generation device is intended for a global clinical study to gather data supporting regulatory submissions in major commercial markets.GlobeNewswireBionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye System Designed to Help the Blind Achieve Greater Mobility and IndependenceBionic Vision Technologies announced interim results from a pilot study of four patients with Retinitis Pigmentosa implanted with its Bionic Eye System. At 44 weeks, patients detected 74.3% of obstacles with the device on versus 4% off, and located objects 70.3% of the time versus 24.4%. The company plans a worldwide clinical trial for the Gen3 device.SBS AustraliaFour Australians gifted bionic sightBionic Vision Technologies has successfully restored partial vision to four Australian patients suffering from Retinitis Pigmentosa through a clinical trial involving bionic eye implants. The technology enables patients to distinguish objects in pixelated greyscale, allowing them to navigate independently without assistance. Following successful lab surgeries, the study has moved to a home-based phase where participants undergo training to perform daily tasks with their new visual capabilities.ABCBionic eye uses brain plasticityBionic Vision Technologies CEO Julie Anne Quinn explained that its bionic eye uses brain plasticity, with patients trained for about a week initially. The company has worked with three retinitis pigmentosa patients and raised $24 million in March 2017. A second model will let patients use the device at home.Startup DailyBionic Vision Technologies raises $23.5 million to commercialise 'bionic eye' implantBionic Vision Technologies raised $23.5 million from Hong Kong investors to commercialize its bionic eye implant. The funds will support manufacturing and a human clinical trial for retinitis pigmentosa, affecting over 1.5 million people. The company also aims to secure regulatory approval and commercial launches.